Zelira Therapeutics Performance dei guadagni passati
Il passato criteri di controllo 0/6
Zelira Therapeutics's earnings have been declining at an average annual rate of -41.7%, while the Pharmaceuticals industry saw earnings growing at 35.4% annually. Revenues have been declining at an average rate of 3.5% per year.
Informazioni chiave
-41.7%
Tasso di crescita degli utili
-20.6%
Tasso di crescita dell'EPS
Pharmaceuticals Crescita del settore | 31.2% |
Tasso di crescita dei ricavi | -3.5% |
Rendimento del capitale proprio | n/a |
Margine netto | -38,513.0% |
Ultimo aggiornamento sui guadagni | 30 Jun 2024 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Zelira Therapeutics Limited's (ASX:ZLD) CEO Will Probably Find It Hard To See A Huge Raise This Year
Nov 08Is Zelira Therapeutics (ASX:ZLD) In A Good Position To Invest In Growth?
Jul 14Here's Why Zelira Therapeutics (ASX:ZLD) Must Use Its Cash Wisely
Jan 19Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?
Sep 25Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?
Jun 03A Quick Analysis On Zelira Therapeutics' (ASX:ZLD) CEO Compensation
Dec 31Ripartizione dei ricavi e delle spese
Come Zelira Therapeutics guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
---|---|---|---|---|
30 Jun 24 | 0 | -37 | 2 | 3 |
31 Mar 24 | 0 | -36 | 3 | 2 |
31 Dec 23 | 0 | -36 | 4 | 1 |
30 Sep 23 | 0 | -21 | 4 | 1 |
30 Jun 23 | 0 | -6 | 5 | 1 |
31 Mar 23 | 1 | -8 | 8 | 2 |
31 Dec 22 | 1 | -10 | 10 | 2 |
30 Sep 22 | 1 | -11 | 11 | 2 |
30 Jun 22 | 2 | -12 | 12 | 1 |
31 Mar 22 | 1 | -11 | 10 | 1 |
31 Dec 21 | 1 | -10 | 8 | 1 |
30 Sep 21 | 1 | -9 | 8 | 2 |
30 Jun 21 | 1 | -9 | 7 | 2 |
31 Mar 21 | 0 | -8 | 6 | 3 |
31 Dec 20 | 0 | -8 | 5 | 4 |
30 Sep 20 | 0 | -8 | 5 | 4 |
30 Jun 20 | 0 | -7 | 4 | 4 |
31 Mar 20 | 0 | -6 | 3 | 3 |
31 Dec 19 | 1 | -4 | 3 | 3 |
30 Sep 19 | 1 | -4 | 2 | 3 |
30 Jun 19 | 1 | -4 | 2 | 2 |
31 Mar 19 | 1 | -3 | 1 | 2 |
31 Dec 18 | 0 | -3 | 1 | 2 |
30 Sep 18 | 0 | -3 | 1 | 2 |
30 Jun 18 | 0 | -2 | 1 | 2 |
31 Mar 18 | 0 | -2 | 1 | 2 |
31 Dec 17 | 0 | -2 | 1 | 1 |
30 Sep 17 | 0 | -4 | 1 | 1 |
30 Jun 17 | 0 | -6 | 2 | 1 |
31 Dec 16 | 0 | -5 | 2 | 0 |
30 Jun 16 | 0 | 0 | 0 | 0 |
Guadagni di qualità: ZLD is currently unprofitable.
Margine di profitto in crescita: ZLD is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: ZLD is unprofitable, and losses have increased over the past 5 years at a rate of 41.7% per year.
Accelerare la crescita: Unable to compare ZLD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: ZLD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (46.5%).
Rendimento del capitale proprio
ROE elevato: ZLD's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.